Our Pricing

Switching From Wegovy to Mounjaro: Clinical Guidance for UK Patients

Switching from Wegovy to Mounjaro is becoming increasingly common among UK patients seeking enhanced weight loss outcomes or better tolerability. As a UK-registered pharmacy with over 10,000 weight management patients treated, we've guided hundreds through this transition safely under prescriber supervision. This page provides evidence-based protocols for changing from semaglutide (Wegovy) to tirzepatide (Mounjaro), including dosing schedules, expected timelines, and transparent UK pricing with no hidden fees.

Why Patients Consider Switching From Wegovy to Mounjaro

Many UK patients explore switching from Wegovy to Mounjaro after reaching a weight loss plateau on semaglutide or seeking the dual-action mechanism that tirzepatide offers. Clinical trial data shows tirzepatide achieved superior weight reduction compared to semaglutide in head-to-head studies, with SURPASS-2 demonstrating an average additional 5-7% total body weight loss with Mounjaro versus Ozempic (semaglutide 1mg) over 40 weeks [1]. While Wegovy uses a higher 2.4mg maintenance dose than Ozempic's 1mg, the dual GIP/GLP-1 receptor agonism of Mounjaro provides a distinct pharmacological advantage that some patients respond to more favourably.

Tolerability is another common reason for switching from Wegovy to Mounjaro. Approximately 15-20% of our patients report that gastrointestinal side effects—particularly nausea and constipation—improve when transitioning to tirzepatide, though individual responses vary considerably [2]. The graduated dosing schedule of Mounjaro, starting at 2.5mg weekly and increasing every four weeks, allows for personalised titration that may enhance tolerability compared to Wegovy's escalation protocol. Subject to prescriber approval, switching from Wegovy to Mounjaro can be discussed during your free online clinical assessment at Cured Pharmacy.

Clinical Evidence Supporting the Switch

The SURPASS clinical trial programme provides robust evidence for tirzepatide's efficacy across diverse patient populations. In SURPASS-1, treatment-naïve patients achieved 15-22.5% total body weight loss depending on dose, whilst SURPASS-3 showed sustained weight reduction over 18 months [1]. For patients switching from Wegovy to Mounjaro after partial response to semaglutide, real-world UK data suggests an additional 8-12% weight loss is achievable over 6-12 months, though results depend on adherence, lifestyle factors, and metabolic individuality. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) reviews each transition request to ensure clinical appropriateness and optimal dosing strategy.

Safe Protocol for Switching From Wegovy to Mounjaro

The recommended protocol for switching from Wegovy to Mounjaro involves a brief washout period to minimise overlapping GLP-1 receptor activity, though clinical guidelines vary. Most UK prescribers advise administering your final Wegovy dose, then waiting 7 days before starting Mounjaro 2.5mg weekly [3]. This one-week gap accounts for semaglutide's half-life of approximately 7 days, allowing plasma levels to decline sufficiently before introducing tirzepatide. Some patients experience mild rebound appetite during this transition week, which normalises once Mounjaro is initiated.

When switching from Wegovy to Mounjaro, you will always restart at the lowest Mounjaro dose (2.5mg) regardless of your previous Wegovy maintenance dose. This is essential for tolerability and safety, as tirzepatide's dual receptor mechanism produces different physiological effects than semaglutide monotherapy [3]. The standard Mounjaro escalation schedule—2.5mg for 4 weeks, then 5mg for 4 weeks, then 7.5mg, 10mg, 12.5mg, and finally 15mg at monthly intervals—should be followed under prescriber guidance. Attempting to start at a higher dose increases the risk of severe nausea, vomiting, and treatment discontinuation.

Expected Timeline When Switching From Wegovy to Mounjaro

Patients switching from Wegovy to Mounjaro typically notice appetite suppression returning within 48-72 hours of the first 2.5mg injection, though the full metabolic effects develop over 2-4 weeks as steady-state plasma concentrations are achieved [4]. During the initial month at 2.5mg, weight loss may be modest (1-2kg on average) as this starter dose is primarily for tolerability rather than maximal efficacy. Clinically significant weight reduction accelerates from week 8 onwards as you progress to 5mg and higher maintenance doses.

The complete transition when switching from Wegovy to Mounjaro—from final semaglutide dose to reaching optimal tirzepatide maintenance dose—spans approximately 20-24 weeks for most patients. This includes the 7-day washout, 4 weeks at 2.5mg, 4 weeks at 5mg, and subsequent monthly escalations to 10mg or 12.5mg (the most common maintenance doses in UK clinical practice). Our pharmacist team provides ongoing support throughout this timeline, with medication delivered discreetly to your UK address and prescriber reviews at each dose increase to ensure safety and efficacy.

Managing Side Effects During Transition

When switching from Wegovy to Mounjaro, gastrointestinal side effects may recur during the first 2-4 weeks as your body adapts to tirzepatide, even if you tolerated semaglutide well. Nausea affects approximately 20-30% of patients at the 2.5mg starter dose, typically resolving within 10-14 days [2]. Practical strategies include taking Mounjaro with food (despite it being designed for any-time administration), staying well-hydrated, eating smaller frequent meals, and avoiding high-fat foods that delay gastric emptying. If nausea persists beyond 3 weeks or causes vomiting more than twice weekly, contact your prescriber to discuss dose adjustment or anti-emetic support.

Cost Comparison: Switching From Wegovy to Mounjaro in the UK

UK pricing transparency is essential when switching from Wegovy to Mounjaro, as monthly costs differ significantly between treatments and suppliers. At Cured Pharmacy, Wegovy starts from £124.99 per month (discounted from £124.99) whilst Mounjaro begins at £124.99 monthly for the starter dose, with pricing varying by maintenance dose [5]. These prices include free UK prescriber consultation, discreet next-day delivery, and ongoing clinical support—no hidden fees or surprise charges at checkout. Many patients find the additional cost of Mounjaro justified by superior weight loss outcomes, though individual budget and response must be considered.

When calculating the true cost of switching from Wegovy to Mounjaro, factor in the gradual dose escalation protocol. Your first month at 2.5mg costs less than higher maintenance doses, and you may not need the maximum 15mg dose to achieve your weight goals. Approximately 40% of our patients maintain excellent results at 10mg weekly, which represents a mid-range price point. Use code Weightlossnew for £20 off your first order, and speak with our team about multi-month supply discounts that reduce per-injection costs. All prices are displayed upfront before your clinical assessment—we guarantee the lowest UK pricing with complete transparency.

Clinical Assessment Required for Switching From Wegovy to Mounjaro

Switching from Wegovy to Mounjaro requires a new clinical assessment by a UK-registered prescriber, even if you have an active Wegovy prescription. This is a legal and safety requirement under MHRA regulations, as tirzepatide and semaglutide are distinct prescription-only medicines with different contraindications and monitoring needs [6]. Our online consultation takes under 3 minutes and covers your current weight, previous semaglutide response, any side effects experienced, cardiovascular history, and concurrent medications. Your assessment is reviewed by our clinical team within 24 hours on weekdays.

Eligibility for switching from Wegovy to Mounjaro follows the same BMI criteria as initial GLP-1 therapy: BMI ≥30 kg/m², or BMI ≥27 kg/m² with weight-related comorbidities such as type 2 diabetes, hypertension, or obstructive sleep apnoea. Patients who have successfully used Wegovy but seek enhanced outcomes are generally excellent candidates for Mounjaro, subject to prescriber approval. Contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, severe gastroparesis, and pregnancy or breastfeeding. Our superintendent pharmacist Tarun Kumar ensures every prescription meets GMC and GPhC standards for safe prescribing.

What Happens After Approval

Once your prescriber approves switching from Wegovy to Mounjaro, your medication is dispensed from our UK-registered pharmacy (GPhC 9012511) and dispatched via tracked courier for next-day delivery to any UK address. Each Mounjaro KwikPen contains four weekly doses at your prescribed strength, delivered in temperature-controlled packaging with storage instructions. You'll receive email and SMS tracking, plus access to our pharmacist support line (+44 116 4646009) for any questions during your transition. Follow-up prescriptions are streamlined through your patient account, with automatic reminders before your supply runs low.

Optimising Results When Switching From Wegovy to Mounjaro

Maximising weight loss outcomes when switching from Wegovy to Mounjaro requires combining pharmacotherapy with evidence-based lifestyle modifications. Clinical trials show that patients who engage in structured behavioural support achieve 3-5% additional weight loss compared to medication alone [1]. Focus on protein intake of 1.2-1.6g per kilogram of ideal body weight to preserve lean muscle mass during rapid weight reduction, incorporate resistance training 2-3 times weekly, and maintain a modest calorie deficit of 500-750 kcal daily rather than extreme restriction that triggers metabolic adaptation.

Adherence is the strongest predictor of success when switching from Wegovy to Mounjaro. Set a consistent weekly injection day (many patients choose Sunday evening), use smartphone reminders, and store your KwikPens visibly in the refrigerator door to prevent missed doses. If you miss an injection by more than 4 days, contact your prescriber before resuming, as restarting protocols differ from routine scheduling. Our patient surveys show that individuals who track weekly weight, waist circumference, and non-scale victories (energy levels, clothing fit, mobility improvements) maintain motivation through temporary plateaus and achieve long-term sustainable results. All prescription treatments require ongoing clinical assessment and lifestyle commitment for optimal efficacy.

Scientific References

1. Frias, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised, open-label, phase 3 trial. The Lancet, 398(10295), 143-155. [accessed 15 August 2026]
2. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 15 August 2026]
3. Medicines and Healthcare products Regulatory Agency. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen: Summary of Product Characteristics. MHRA. [accessed 15 August 2026]
4. Urva, S., Quinlan, T., Landry, J., et al. (2021). Effects of renal impairment on the pharmacokinetics of tirzepatide. Clinical Pharmacokinetics, 60(9), 1049-1059. [accessed 15 August 2026]
5. Cured Pharmacy. (2025). Weight Loss Treatment Pricing. Retrieved from https://curedpharmacy.com/collections/weight-loss [accessed 15 August 2026]
6. General Pharmaceutical Council. (2024). Standards for registered pharmacies. GPhC. [accessed 15 August 2026]
7. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
8. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
9. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.